On August 6, 2026, the clinical trial registry listed the EMANATE study status as completed. The trial, titled "EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway," is registered under identifier NCT05093634. It is a Phase 3 study evaluating setmelanotide in patients with specific gene variants affecting the MC4R pathway. Setmelanotide currently holds approved regulatory status. The update reflects a change in trial status only and does not include any reported results or outcomes. No efficacy or safety data from this trial are included in this update. Readers should not assume any conclusions about benefit or harm based solely on a status change to completed. Further details on trial design, enrollment, and any eventual results can be found through the official registry listing. For additional context on setmelanotide, including its approved uses and background, readers can consult the compound overview.</body_markdown>
<parameter name="sources">["https://clinicaltrials.gov/study/NCT05093634"]